Molecular Basis for Statin-Induced Muscle Toxicity: Implications and Possibilities
- 5 August 2008
- journal article
- review article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 9 (8) , 1133-1142
Abstract
Statins are widely used to treat hypercholesterolemia, a known risk factor for atherosclerosis. These drugs can lead to a number of side effects in muscle, including rhabdomyolysis; however, the mechanism of muscle injury is poorly defined. We review the clinical characteristics of this diverse syndrome, as well as the biochemical mechanisms that might provide an explanation for the toxicity of these agents. New findings implicating atrogin-1, a gene required for muscle atrophy, in the pathophysiology of statin-induced muscle injury are discussed, as well as implications of these novel discoveries.Keywords
This publication has 103 references indexed in Scilit:
- The initiation factor eIF3‐f is a major target for Atrogin1/MAFbx function in skeletal muscle atrophyThe EMBO Journal, 2008
- The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trialsCanadian Medical Association Journal, 2008
- Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteinsJournal of Clinical Investigation, 2007
- The Role of Coenzyme Q10 in Statin-Associated MyopathyJACC, 2007
- Genetic determinants of statin intoleranceLipids in Health and Disease, 2007
- A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in MusclePLOS ONE, 2006
- Human Coenzyme Q10 DeficiencyNeurochemical Research, 2006
- PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcriptionProceedings of the National Academy of Sciences, 2006
- Toxicity of statins on rat skeletal muscle mitochondriaCellular and Molecular Life Sciences, 2006
- Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibresNature, 2002